[Urinary lithiasis secondary to indinavir in an HIV-positive patient].
OBJECTIVE
Indinavir is a protease inhibitor used in the treatment of HIV with a lithogenic capacity as a urological side effect. The pathogenesis, diagnosis and treatment of indinavir urolithiasis are briefly reviewed.


METHODS
A 37-year-old male, seropositive for HIV on treatment with indinavir, lamiduvine and zidovudine, consulted for colicky left lumbar pain, nausea, vomiting and dark urine for the past three days.


RESULTS
Patient evaluation showed a nonfunctioning left kidney and ureterohydronephrosis of unknown origin. URS showed a yellowish, friable material with a mucinous appearance that occupied the entire lumen of the ureter. Fragmentation was achieved with the lithotriptor probe. Six months later the patient had fully recovered and was asymptomatic.


CONCLUSIONS
The incidence of protease inhibitor-induced urolithiasis is increasing. This condition should be distinguished from uric acid calculi whose treatment will aggravate the indinavir urolithiasis.
Moyano Calvo
J L
JL
Servicio de Urología, Hospital Universitario Virgen Macarena, Sevilla, España.
Huesa Martínez
I
I
Cruz Navarro
N
N
Leal Arenas
J
J
León Dueñas
E
E
Morales López
A
A
Maestro Durán
J L
JL
Ramírez Mendoza
A
A
D000328:Adult; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006679:HIV Seropositivity / Q000150:complications*; D006801:Humans; D019469:Indinavir / Q000009:adverse effects*; D007669:Kidney Calculi / Q000139:chemically induced*; D008297:Male
D017320:HIV Protease Inhibitors; D019469:Indinavir